New drug trial targets Tough-to-Treat melanoma after immunotherapy fails
Disease control
Recruiting now
This study is testing an experimental drug called mirdametinib in people with advanced melanoma that has a specific genetic change (an NF1 mutation) and has continued to grow despite previous immunotherapy. The main goals are to see if the drug is safe and if it can slow or stop …
Phase: PHASE2 • Sponsor: Kevin Kim, MD • Aim: Disease control
Last updated Apr 09, 2026 19:33 UTC